Accéder au contenu
Merck
Toutes les photos(1)

Documents

T4827

Sigma-Aldrich

Trandolapril

≥98% (HPLC), white, powder

Synonyme(s) :

(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C24H34N2O5
Numéro CAS:
87679-37-6
Poids moléculaire :
430.54
Numéro MDL:
MFCD00865776
Code UNSPSC :
12352200
ID de substance PubChem :
329826801
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white

Solubilité

DMSO: ≥20 mg/mL

Auteur

Abbott

Chaîne SMILES 

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O

InChI

1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

Clé InChI

VXFJYXUZANRPDJ-WTNASJBWSA-N

Informations sur le gène

human ... ACE(1636)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).

Actions biochimiques/physiologiques

Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2.
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.

Caractéristiques et avantages

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Notes préparatoires

Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360D

Classification des risques

Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

Lisinopril ≥98% (HPLC)

Sigma-Aldrich

L6292

Lisinopril

Irinotecan hydrochloride topoisomerase inhibitor

Sigma-Aldrich

I1406

Irinotecan hydrochloride

O D Pedersen et al.
Circulation, 100(4), 376-380 (1999-07-27)
Studies have suggested that ACE inhibitors have an antiarrhythmic effect on ventricular arrhythmias. Whether they have an effect on atrial fibrillation is unknown. We investigated the effect of ACE inhibition with trandolapril on the incidence of atrial fibrillation in patients
Alberto F Rubio-Guerra et al.
Therapeutic advances in cardiovascular disease, 5(4), 193-197 (2011-07-09)
Adiponectin is secreted from adipose tissue and exhibits a protective effect against cardiovascular disease; plasma adiponectin concentrations are decreased in type 2 diabetic and in hypertensive patients. The aim of this study was to compare the effect of trandolapril (T)
Morten Schou et al.
European journal of clinical investigation, 41(11), 1237-1244 (2011-05-11)
Hyponatremia is a known prognostic factor for mortality in patients with heart failure but has not been extensively studied in patients with myocardial infarction (MI). This study was, therefore, designed to evaluate whether plasma sodium and hyponatremia (< 135 mM)
Ivana Vaněčková et al.
Kidney & blood pressure research, 35(5), 382-392 (2012-04-11)
Our previous studies in rats with ablation nephrectomy have shown similar cardiorenal protective effects of renin-angiotensin system (RAS)-dependent treatment (combination of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker) and RAS-independent treatment (combination of α- and β-adrenoreceptor antagonist and diuretics).
Tobias Gerhard et al.
BMC medical research methodology, 12, 119-119 (2012-08-08)
Due to time-dependent confounding by blood pressure and differential loss to follow-up, it is difficult to estimate the effectiveness of aggressive versus conventional antihypertensive combination therapies in non-randomized comparisons. We utilized data from 22,576 hypertensive coronary artery disease patients, prospectively
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique